ODTX Stock Forecast & Price Target

Odyssey Therapeutics is compelling because OD-001 has already shown differentiated Phase 2a ulcerative colitis activity, delivering a 2.6-point mMS improvement and 27% clinical remission versus roughly 10% historical placebo, while remaining well tolerated with no Grade 3+ TEAEs, SAEs, or liver signals. Its mechanistic edge is that RIPK2 scaffolding inhibition attacks an upstream innate-immune node, potentially overcoming cytokine redundancy and resistance seen with biologics, and the planned Phase 2b monotherapy and vedolizumab-combination studies in 2H26 and 2H27 create clear catalysts. Financially, the company’s $433M cash balance and expected runway into 2H28 reduce near-term dilution risk, while a broader pipeline including OD-002, OD-003, and OD-004 adds meaningful upside optionality.

Odyssey Therapeutics is viewed negatively because its lead programs face substantial clinical risk, with lower-than-expected efficacy, possible failure to reach statistical significance, and uncertainty that combination regimens will outperform monotherapy or avoid added safety issues. The thesis is further weakened by a crowded competitive landscape and weak target validation, including the 2024 termination of Boehringer Ingelheim’s RIPK2 study as a likely negative read-through, while Odyssey itself has only ~48M shares post-IPO and remains exposed to limited data quality and regulatory setbacks. Financially, the company is expected to post GAAP EPS of ($1.13) in 3Q26 and ($6.13) in 2026, remain operating cash flow negative in the near and mid-term, and not turn cash flow positive until 2034, implying likely future dilution.